Jasper Therapeutics Inc (JSPR) - Market Cap to Net Income Ratio

Corporate emblem and logo of Jasper Therapeutics, Inc. (JSPR)

The Jasper Therapeutics (JSPR) biotech model is currently undergoing a phase of expanding production protocols, which is temporarily increasing R&D costs. This price chart on GURU.Markets captured the -0.40 metric. The business relies on research centers in California and a network of external CDMO sites. The company's strategy is based on implementing gentle antibodies instead of aggressive chemistry during bone marrow transplant preparation.

JSPR jaspertherapeutics.com: Price to Earnings Ratio in the range 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for Jasper Therapeutics Inc (JSPR)

- market price and analyst price targets:
Market Price Jasper Therapeutics|JSPR - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization JSPR|JSPR - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Net Asset Value per Share Jasper Therapeutics|JSPR - Company Net Assets|Market Value to Book Value jaspertherapeutics.com|JSPR - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Jasper Therapeutics|JSPR - Long-Term Debt to Capital|Current Liabilities to Capital jaspertherapeutics.com|JSPR - Company Debts|Debt to Book Capitalization Ratio Jasper Bio|JSPR - Company Long-Term Debt|Company Short-Term Debt Jasper Therapeutics|Intermediate Coverage Ratio jaspertherapeutics.com
- business earnings and investment ratios data:
JSPR - Net Profit|Projected Net Profit Jasper Therapeutics|JSPR - P/E Multiple|Projected Price to Earnings Ratio jaspertherapeutics.com|JSPR - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Jasper Therapeutics Inc|JSPR - Operating profit EBITDA|Net earnings per one share for the last twelve months Jasper Therapeutics|JSPR - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months jaspertherapeutics.com|JSPR - Net earnings per share growth this year|Projected earnings per share increase next year Jasper Therapeutics
- issuer revenue and sales details:
JSPR - Revenue and Sales Volume|Company Future Revenue Jasper Therapeutics|JSPR - P/S Multiple|Market Cap to Future Revenue Ratio Jasper Bio
Comprehensive company analysis:Jasper Therapeutics Inc
Signature product of Jasper Therapeutics, Inc.

Jasper Therapeutics is transforming bone marrow transplant protocols by replacing toxic chemotherapy with targeted antibodies, making the P/E ratio dynamics a key indicator of market expectations for capitalization. This multiple relates the current share price to net income, allowing investors to mathematically determine the investment payback period and distinguish fundamental business growth from short-term speculative price fluctuations.

Analysis of competing companies

Market Cap to Earnings Legend Biotech Corporation LEGN|P/E Multiple SANA|Autolus Therapeutics (AUTL) - Market Cap to Net Income Ratio|Allogene Therapeutics, Inc. - Price to Earnings Ratio|Cartesian Therapeutics, Inc. (RNAC) - Market Cap to Earnings|CLLS: Price to Earnings Ratio|Company Value to Net Income CRBU (Caribou Biosciences, Inc.)|TIL: P/E Multiple|Price to Earnings Ratio Genenta Science SpA|IPSC (Century Tx) - P/E Multiple|Market Cap to Earnings sentibio.com SNTI|Price to Earnings Ratio Adaptimmune Therapeutics (ADAP)|Price to Earnings Ratio CERO (CERo Therapeutics Holdings, Inc.)|Price to Earnings Ratio Alaunos TCRT|achillestx.com - Price to Earnings Ratio|CRGX: Price to Earnings Ratio|Company Value to Net Income PSTX (Poseida Therapeutics)|TSVT: P/E Multiple|Market Cap to Net Income Ratio Gracell Biotechnologies Inc. GRCL